Netherlands Cancer Institute (NKI) Selects Proscia To Drive Personalized Diagnosis

By Author Proscia | January 18, 2023

Proscia, a leading provider of digital and computational pathology solutions, has announced that the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centers in Europe, will deploy its Concentriq Dx* platform.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

Our website uses cookies. By using this site, you agree to its use of cookies.